PR Newswire 科技新闻稿·· 1 小时前AI 评分15
AMCP Market Insights：ESR1 突变晚期乳腺癌生物标志物检测面临不确定性，支付方正权衡更早检测与靶向治疗新类别
AMCP Market Insights Findings Show Uncertainty in Biomarker Testing for ESR1-Mutated Advanced Breast Cancer as Payers Weigh Earlier Detection and a Growing Class of Targeted Therapies
AI 导读
AMCP Market Insights 项目发现，ESR1 突变晚期乳腺癌的生物标志物检测与治疗范式演进快于支撑其管理的证据，最佳检测参数不明导致检测实践不一致、医疗与药房福利覆盖摩擦及诊疗延迟。
来源：PR Newswire 科技新闻稿 · prnewswire.com